Baxter International Inc. Share Price Berne S.E.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Delayed Berne S.E. 17:00:00 06/04/2023 BST 5-day change 1st Jan Change
38.11 CHF +3.50% Intraday chart for Baxter International Inc. -.--% -.--%

Financials

Sales 2024 * 15.11B 13.47B 1,194B Sales 2025 * 15.66B 13.96B 1,237B Capitalization 17.19B 15.32B 1,357B
Net income 2024 * 703M 626M 55.52B Net income 2025 * 950M 846M 75.02B EV / Sales 2024 * 1.79 x
Net Debt 2024 * 9.85B 8.77B 778B Net Debt 2025 * 9.06B 8.07B 715B EV / Sales 2025 * 1.68 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
15.1 x
Employees -
Yield 2024 *
3.54%
Yield 2025 *
3.68%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors CI
Transcript : Baxter International Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM
Transcript : Baxter International Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 09:30 AM
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy CI
Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating MT
Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Baxter International's Clinolipid Injection Approved for Expanded Use in US MT
Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication CI
TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 MT
Declaration of Voting Results by Baxter International Inc CI
Baxter International Keeps Quarterly Cash Dividend at $0.29 a Share, Payable July 1 to Shareholders as of May 31 MT
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024 CI
UBS Adjusts Price Target on Baxter International to $40 From $42, Maintains Neutral Rating MT
Evercore ISI Adjusts Price Target on Baxter International to $46 From $50 MT
Jefferies Adjusts Price Target on Baxter International to $43 From $45 MT
More news
Managers TitleAgeSince
Chief Executive Officer 61 30/09/15
Director of Finance/CFO 54 17/10/23
Chief Tech/Sci/R&D Officer - 31/12/16
Members of the board TitleAgeSince
Director/Board Member 73 05/02/17
Director/Board Member 64 09/05/22
Director/Board Member 64 17/02/19
More insiders
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
33.73 USD
Average target price
45.44 USD
Spread / Average Target
+34.71%
Consensus